DEA Telemedicine Prescribing Flexibilities After December 31, 2026: What Telehealth Clinics Should Prepare
Update log: This page was last verified against the DEA and Federal Register on October 13, 2026. Telemedicine prescribing rules are actively evolving; re-check the current deadline before relying on any date below.
As of this writing, the DEA's pandemic-era telemedicine flexibilities for prescribing controlled substances, which let practitioners prescribe Schedule II-V medications via telehealth without a prior in-person exam, are extended through December 31, 2026. This is the fourth temporary extension since the flexibilities began in 2020. No permanent rule has taken effect yet, so telehealth clinics prescribing controlled substances, including testosterone, ketamine, and buprenorphine programs, should treat this date as a real deadline and plan around it rather than assuming another extension is guaranteed.
How We Got Here
The flexibilities trace back to March 2020, when the COVID-19 public health emergency suspended the Ryan Haight Act's general requirement of an in-person exam before prescribing controlled substances by telemedicine. The DEA and HHS have extended the flexibilities several times since the emergency ended, most recently through December 31, 2026, while the agency works toward a permanent telemedicine prescribing framework, including a potential special registration process for telehealth prescribers.
What's Actually at Stake
If the flexibilities lapse without a replacement rule in place, telehealth practices would face what's been called a "telemedicine cliff": a sudden return to requiring an in-person medical evaluation before prescribing most controlled substances. That would disrupt new-patient intake for any program built around a fully virtual visit, particularly:
- Testosterone replacement therapy programs
- Ketamine-assisted treatment programs
- Buprenorphine and other medication-assisted treatment for opioid use disorder (which has its own, separate final rule already in effect)
- Any GLP-1 or weight-loss telehealth program prescribing scheduled appetite suppressants
Audio-only telehealth also carries its own, narrower set of allowances, mainly for buprenorphine, so practices relying on phone-only visits for other controlled substances should check whether that pathway is still covered under the current extension.
What Telehealth Clinics Should Do Now
- Document which patients and prescriptions depend on the flexibility. You can't react to a rule change quickly if you don't know which active patients would need an in-person exam under a reversion to Ryan Haight Act defaults.
- Build an in-person contingency path. Identify a referral network or in-person exam option in the states where your patients are located, so you have somewhere to route patients if a final rule requires it.
- Track the Federal Register directly, not just secondary summaries. DEA and HHS announcements move fast and sometimes change scope (audio-only versus audio-video, which schedules are covered) between extensions.
- Review your medical oversight structure. A telehealth practice with a properly engaged medical director is better positioned to adapt protocols quickly if requirements change mid-program.
- Revisit this page before December 15, 2026. We re-verify this deadline as it approaches; if you're relying on it for patient communications, check back rather than citing this date from memory.
This Affects More Than Prescribing Workflows
Beyond the prescribing mechanics, clinics should also confirm their broader telehealth compliance, oversight, and EHR setup can support whatever final rule eventually lands, since documentation and recordkeeping requirements are likely to tighten regardless of which specific registration framework the DEA finalizes. For practices operating in multiple states, our guide to structuring a remote medical oversight program covers how to keep oversight consistent as rules shift state by state.
Talk to Us Before Your Program Prescribes Into a Gap
Telehealth Services from Wellness MD Group help telemedicine clinics structure medical oversight that can adapt as DEA rules evolve. If your program prescribes controlled substances by telehealth, talk to us now about in-person exam and oversight options. Call (877) 540-7553 or request a consultation.
Frequently Asked Questions
When do the DEA's telemedicine prescribing flexibilities expire?
As of this writing, they're extended through December 31, 2026. This is the fourth temporary extension, and no permanent rule has been finalized, so confirm the current status before relying on this date for patient-facing communications.
Does this affect buprenorphine prescribing differently?
Yes. A separate final rule covering buprenorphine prescribing via telemedicine took effect in late 2025 and operates alongside the broader extension. Programs should confirm which framework applies to their specific prescribing workflow.
What happens if no further extension or final rule arrives?
Telehealth prescribers would likely need to revert to requiring an in-person medical evaluation before prescribing most controlled substances under the Ryan Haight Act's general rule, which would disrupt fully virtual new-patient intake for affected programs.
Should we pause new patient intake for controlled-substance programs?
Not necessarily, but you should have a documented contingency plan and know exactly which active patients and prescriptions would be affected by a rule change, so you can act quickly rather than scrambling after the fact.